NDAOPHTHALMICOINTMENT
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLOROPRYL (isoflurophate) is an ophthalmic ointment approved in 1957 for treating glaucoma and accommodative esotropia by reducing intraocular pressure through parasympathomimetic activity. It is a cholinesterase inhibitor that increases acetylcholine levels in the eye, enhancing aqueous humor outflow and pupillary constriction.
LOE Approaching
As an approaching LOE asset with low linked job count, this product likely supports a minimal commercial team in transition planning and defensive strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FLOROPRYL offers minimal career advancement opportunity as a legacy, declining-revenue asset with zero linked job openings. Work on this product typically involves lifecycle management, depletions, and transition planning rather than growth initiatives.
Product Manager (defensive)Market Access Manager
Worked on FLOROPRYL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.